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Prevailing knowledge gaps in linking speciﬁc molecular changes to apical outcomes and methodological
uncertainties in the generation, storage, processing, and interpretation of 'omics data limit the appli-
cation of 'omics technologies in regulatory toxicology. Against this background, the European Centre for
Ecotoxicology and Toxicology of Chemicals (ECETOC) convened a workshop Applying 'omics technologies
in chemicals risk assessment that is reported herein. Ahead of the workshop, multi-expert teams drafted
frameworks on best practices for (i) a Good-Laboratory Practice-like context for collecting, storing and
curating 'omics data; (ii) the processing of 'omics data; and (iii) weight-of-evidence approaches for
integrating 'omics data. The workshop participants conﬁrmed the relevance of these Frameworks to
facilitate the regulatory applicability and use of 'omics data, and the workshop discussions provided
input for their further elaboration. Additionally, the key objective (iv) to establish approaches to connect
'omics perturbations to phenotypic alterations was addressed. Generally, it was considered promising to
strive to link gene expression changes and pathway perturbations to the phenotype by mapping them to
speciﬁc adverse outcome pathways. While further work is necessary before gene expression changes can
be used to establish safe levels of substance exposure, the ECETOC workshop provided important in-
centives towards achieving this goal.
Crown Copyright © 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
'Omics technologies hold the promise of generating compre-
hensive toxicologically relevant information on molecular changes
in cells and tissues more quickly, more accurately and with less
resources than ever before (ECETOC, 2008). They provide ap-
proaches to precisely measure substance-induced molecular per-
turbations that are associated with adverse outcomes in animals
and humans. Thereby, these technologies have the potential to
improve chemical safety assessment and, at the same time, to reﬁne
and reduce animal testing in regulatory toxicology. 'Omics tech-
nologies are poised to increase the number of substances that can
be efﬁciently tested in a given time and to increase the number of
molecular and cellular endpoints that can be detected and simul-
taneously evaluated. Also, 'omics technologies have the potential to
identify new hazards through enhanced coverage of biological (or
biochemical) pathways (cf. Box for deﬁnition) during toxicological
screening, and this information can be mined for the development
of new, reliable biomarkers for the detection of adverse effects
(ECETOC, 2010). However, in addition to prevailing knowledge gaps
in linking speciﬁc molecular changes to apical outcomes, current
methodological uncertainties in interpreting and assessing data
limit the application of 'omics technologies in regulatory toxi-
cology. This includes issues surrounding the generation, storage,
processing, and interpretation of 'omics data, as well as a lack of
experience with such kind of data across the regulatory commu-
nity. Hence, best practices for generating, storing, processing, and
interpreting 'omics data are needed as one starting point so that the
outcomes of 'omics-based studies can be reliably veriﬁed and
conﬁdently integrated into regulatory hazard and risk assessment.
Against this background, the European Centre for Ecotoxicology
and Toxicology of Chemicals (ECETOC) convened a workshop
entitled Applying 'omics technologies in chemicals risk assessment
that took place from 10 to 12 October 2016 in Madrid, Spain. Thirty-
six invited experts from Europe, Canada, Japan, and the United
States, attended this workshop representing the European Com-
mission; the Organisation for Economic Cooperation and Devel-
opment (OECD); national authorities from EU Member States, EUassociated countries and North America; academia; industry and
independent consultants. An additional three experts contributed
to the workshop in the form of video or dial-in presentations (cf.
Supplementary Information for the list of workshop participants).
The 2016 ECETOC workshop, reported herein, was conceived to
contribute to fulﬁlling the recommendations from previous ECE-
TOC workshops on the Application of ‘omic technologies in toxicology
and ecotoxicology: Case studies and risk assessment (ECETOC, 2008),
'Omics in (eco)toxicology: case studies and risk assessment (ECETOC,
2010), and 'Omics and risk assessment science (ECETOC, 2013). The
recommendations from these workshops addressed the need to
deﬁne quality standards on the design and performance of 'omics-
based studies and to communicate these quality standards as best
practices. Such guidance would serve to enhance the regulatory
acceptance and use of 'omics data (ECETOC, 2008, 2010, 2013).
Ahead of the 2016 workshop, ECETOC multi-expert teams
drafted frameworks addressing the key objectives to establish best
practices for (i) a Good-Laboratory Practice (GLP)-like context for
collecting, storing and curating 'omics data; (ii) the processing of
'omics data, and (iii) weight-of-evidence (WoE) approaches for
integrating 'omics data. Additionally, the key objective (iv) to
establish approaches to connect 'omics perturbations to phenotypic
alterations was addressed, albeit without an in-advance draft of a
framework.
While the focus of the Workshop was directed towards tran-
scriptomics, it is anticipated that some of the concepts developed at
the Workshop will be applicable to other 'omics tools recognising
the differences in the various technologies.
As Alan Poole (Secretary General of ECETOC, Belgium) explored
in the opening presentation, the workshop aimed to further
elucidate these four key objectives and the contents of the draft
frameworks. Invited presentations served to provide background
information on relevant case studies or related ongoing activities.
Importantly, four breakout sessions and extensive plenary sessions
provided ample opportunity for in-depth discussions. The recom-
mendations from the workshop would be used to advance the
drafted frameworks to ensure their ﬁtness for purpose, i.e. for
regulatory acceptance and use. Once ﬁnalised, the frameworks
Box
Definition of biological pathways and adverse outcome
pathways.
Adverse outcome pathway (AOP): A linear sequence of key
events from a molecular initiating event (MIE) to an adverse
(toxic) effect at the individual level (for human health) or
population level (for environmental health). Key events in an
AOP are scientifically defensible events that are necessary,
but not always sufficient, for an adverse outcome. AOPs
should be definable, measureable, and plausible, and they
should provide a causal link between the events occurring
from the initial interaction of a substance with its molecular
target (i.e. the MIE) and the adverse outcome (Ankley et al.,
2010; OECD, 2012, 2013). Unlike modes-of-action (see
below), AOPs are substance-agnostic and not species-
specific, and thus do not consider factors that are directly
related to the exposure to a given substance, e.g., absorption,
distribution, metabolism, and excretion (ECETOC, 2017).
Mode-of-action (MoA): The biologically plausible sequence
of substance-specific key events that are specific to the
exposure to a given substance, starting with the definition
of the substance and proceeding through the interaction of
the substance or its metabolites with a cell, to functional
and anatomical changes leading to an observed effect
supported by robust experimental observations and
mechanistic data (Sonich-Mullin et al., 2001; Boobis et al.,
2009; Fenner-Crisp and Dellarco, 2016).
Biological (or biochemical) pathway: There is no universal
definition of a biological (or biochemical) pathway (ECETOC,
2013). Throughout this workshop report, the following
definition is used: A series ofmolecular events occurring in a
cell (or extracellularly) that leads to a certain product or an
intra- or extracellular alteration. A pathway can, for example,
trigger the assembly of newmolecules, andwill thus include
direct substance-target interactions, cellular signalling and
cellular regulatory processes (adapted from: US National
Human Genome Research Institute; cf. https://www.
genome.gov/27530687/biological-pathways-fact-sheet/).
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'omics data. Importantly, the frameworks were intended to provide
baselines on best practice but not to be prescriptive.
Alan Poole further explained that the goal to generate consensus
of opinion on the steps needed to achieve best practices for the
generation and storage, processing and interpretation of 'omics
data for the hazard and risk assessment of substances is highly
relevant in a global context. Generally, the drafted frameworks
were prepared to cover all purposes of regulatory use of 'omics
data, including use in supporting or predicting no (or lowest)
observed adverse effect levels (NOAEL or LOAEL) as points of de-
parture (PoD) for hazard assessment, and investigating adverse
outcome pathways (AOPs) or substance-speciﬁc modes-of-action
(MoAs) (Ankley et al., 2010; OECD, 2012, 2013;Meek et al., 2014); cf.
Box for deﬁnitions. Further deﬁnitions of 'omics-related terminol-
ogy and details on the regulatory use of 'omics data as well as on
the need to develop frameworks on the collection and storage,
processing, and interpretation of 'omics data are provided in a
background document (Sauer et al., 2017) in this journal
Supplement.
In accordance with its four key objectives, the workshop was
divided into four work streams, preceded by an opening session.Work stream 1 covered the generation and storage of 'omics data,
work stream 2 the processing of 'omics data, and work streams 3
and 4 the interpretation of 'omics data (Fig. 1).
Below, the topics and concepts that were addressed in the
presentations are summarised, and the main issues and recom-
mendations that arose during the breakout sessions and plenary
discussions (moderation: Alan Poole and Madeleine Laffont, ECE-
TOC, Belgium) are highlighted.
2. Opening session: regulatory perspectives on scientiﬁc
needs, challenges and opportunities of 'omics technologies
Alan Poole chaired the opening session, in which representa-
tives from the OECD, national authorities and the European Com-
mission provided keynote presentations of their perspectives on
scientiﬁc needs, challenges and opportunities of 'omics-based
technologies.
2.1. Presentations opening session
Eeva Leinala (OECD, France) summarised OECD activities on the
development of AOPs (OECD, 2013) and integrated approaches to
testing and assessment (IATAs). IATAs and integrated testing stra-
tegies (ITSs) serve to combine different (non-animal) test methods
reﬂecting the different steps of an AOP (OECD, 2015). The ongoing
OECD Extended Advisory Group on Molecular Screening and Tox-
icogenomics (EAGMST) is dedicated to the topic of use of 'omics-
based technologies for toxicological evaluations, while also sup-
porting AOP development and MoA assessment (OECD, 2014).
Matt Martin (National Center for Computational Toxicology,
U.S. Environmental Protection Agency (EPA), USA) spoke about high
throughput and transcriptomics work being conducted at the U.S.
EPA. This work contributes to the establishment and use of in vitro
PoDs that might be suitable for hazard assessment, to the identi-
ﬁcation of primary and secondary molecular targets of substances
via proﬁle matching with reference substances, and to the identi-
ﬁcation of molecular initiating events (MIEs; i.e. the ﬁrst event in an
AOP), as well as subsequent key events.
Aldert H. Piersma (Centre for Health Protection, National
Institute for Public Health and the Environment (RIVM), The
Netherlands) took the example of embryonic stem cell neural dif-
ferentiation to highlight important aspects to consider when
establishing best practices for 'omics studies. He highlighted that a
scientiﬁcally sound study design is pivotal for a successful study
outcome. Further, it should be ensured that the statistical analysis
of 'omics data does not override the evaluation of their biological
relevance since the magnitude and/or variance of the gene
expression response does not provide useful information about the
dynamic range or the dose-response relationship of the measured
response. He cautioned that in mixed cell type tissues, individual
genes might show limited responses, whereas their expression
changes might be highly signiﬁcant when related to speciﬁc cell
types. Further, single gene expression changes might gain weight
when pathways of related genes, and their expression changes, are
analysed. At best, studies should address time courses and dose-
responses of substance-induced gene expression changes and not
only single time points and doses. In evaluating the outcomes of
'omics studies, the reproducibility of gene expression changes in
more than one test system improves the overall WoE, and in-
vestigators should strive to understand the biology of the test
systems used.
Tewes Tralau (German Federal Institute of Risk Assessment
(BfR), Germany) presented a regulator's view on the challenges and
perspectives for using 'omics studies for regulatory toxicology.
With the advent of 'omics, high throughput testing, three-
Fig. 1. Steps of 'omics studies (taking the example of transcriptomics) and their correspondence to the work streams of the ECETOC workshop.
GLP: Good Laboratory Practice; WoE: Weight-of-evidence.
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systems, the pressure to bring such methods to regulatory use
has increased as has the debate about their usability and applica-
tion domains (Tralau et al., 2015). Yet, regulators continue to take a
cautious stand on this matter. Currently, 'omics data are mostly
seen as supplementary information, for example for MoA analysis
or to substantiate the application of read-across techniques. Main
obstacles to the implementation of 'omics-based methods are un-
certainties in how to use and validate such data, as well as their
predictivity and performance for hazard and risk assessment when
compared to established test methods. Moreover, in absence of
clear causal relationships, predictability can be an issue. Without
changes in long-established practices, it will be difﬁcult to readily
adapt 'omics data for the purpose of quantiﬁable risk assessment or
to transpose test results to the classiﬁcation and labelling (C&L) of
substances, as implemented in the United Nations Globally
Harmonised System of Classiﬁcation and Labelling of Chemicals (GHS;
United Nations, 2015) and Regulation (EC) No 1272/2008 on the
classiﬁcation, labelling and packaging of substances and mixtures
(CLP; EP and Council of the EU, 2008). From a current regulatory
perspective, the biggest promise of 'omics data is use in ITSs, to
identify biomarkers of adverse effects and to prioritise testing. Key
scientiﬁc, legal and regulatory issues thus have to address the
following questions: Is it the aim to provide supplementary infor-
mation, to replace traditional toxicological endpoints or to address
unresolved toxicological issues? How can molecular measures be
converted into quantitative (or probabilistic) measures of adversity
that are suitable for risk assessment? Can relevant biomarkers be
identiﬁed, i.e. speciﬁc genes that deﬁne the pathological point-of-
no-return that will ultimately lead to an adverse effect? How
shall 'omics data be analysed and validated? Do validation studies
include the right standards? Are the currently used test systems
sufﬁciently complex? Also discussed was the need for blinded pilot
studies (in which information on the test substances was not dis-
closed to the experimenter until after the completion of the study)
in order to obtain a better understanding of the performance of
'omics-based methodologies in routine practice.
Andrew Worth (European Commission, Joint Research Centre,European Reference Laboratory for Alternatives to Animal Testing
(EURL ECVAM), Italy) added further perspectives on the regulatory
use of 'omics technologies. The primary mission of the EURL
ECVAM is tomake available validated test methods that support the
3Rs principle to replace, reduce and reﬁne animal testing that was
originally introduced by Russell and Burch (1959). Possible appli-
cations of 'omics studies include the development of AOPs; the
quality assurance of cell lines with respect to their identity, genetic
stability, and contamination; the provision of supplementary data
in WoE approaches; the support of grouping of substances and
read-across technologies; and, ﬁnally, to set PoDs for risk assess-
ment and to provide information relevant for C&L. Generally,
'omics-based test methods need to be validated to demonstrate
their reliability and reproducibility, theirmechanistic relevance and
utility, prior to routine use in these applications.
On behalf of Leming Shi (Fudan University, Shanghai, China),
Weida Tong (National Center for Toxicological Research (NCTR),
U.S. Food and Drug Administration (FDA), USA) provided an over-
view on lessons learned from the ﬁrst parts of the Microarray
Quality Control (MAQC) and Sequencing Quality Control (SEQC)
projects in striving for reproducible 'omics data for risk assessment.
The goal of the FDA-led community-wide MAQC consortiumwas to
assess the technical performance and application of 'omics tech-
nologies in clinical application, safety assessment and precision
medicine. The MAQC consortium was established in 2005 and, by
end of 2014, had completed three projects evaluating the perfor-
mance of microarrays, genome-wide association studies and RNA-
sequencing (RNA-Seq), with particular reference to:
1. The reproducibility of transcriptomics data, deﬁned as the per-
centage of overlapping genes between lists of differentially
expressed genes (DEGs),
2. Between-experiment concordance, within-laboratory repeat-
ability, and
3. Cross-platform reproducibility.
In these projects, relative measures, but not absolute measure-
ments, agreed well across laboratories. Slight changes in the
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composition of the DEG lists. Further, the responsiveness of the
individual test animals accounted for approximately 30% of the data
variation. Using fold changes in gene expression (as compared to
the expression levels observed in control groups) together with p-
value thresholds to identify DEGs enhanced reproducibility, while
still optimally balancing sensitivity and speciﬁcity. Thus, the work
of the MAQC consortium has advanced microarray and RNA-Seq
analytical pipelines that can be leveraged for developing analyt-
ical frameworks and best practices. Further details on the MAQC
project are provided in Sauer et al. (2017) in this journal
Supplement.
3. Work stream 1: establishing a GLP-like context for
collecting, storing and curating 'omics-based data
Chair: Ben van Ravenzwaay (BASF SE Germany; Chair of the
ECETOC Scientiﬁc Committee)
3.1. Presentations work stream 1
Hans-Martin Kauffmann (BASF SE, Germany) presented the
ECETOC concept for quality assurance of new technology data
considering GLP requirements. The details on this framework are
provided in Kauffmann et al. (2017) in this journal Supplement.
Brieﬂy, a GLP environment comprises a standard operating pro-
cedure (SOP) system, proper pre-planning and conduct documen-
tation as well as independent quality assurance inspections (OECD,
1998). Particular challenges to fulﬁl GLP requirements for 'omics-
based studies are likely to be associated with (1) the deﬁnition of
raw data; (2) the reproducibility of ﬁnal results based on stored raw
data; (3) the transparent description of all data processing steps;
and (4) the validation of procedures and software (that could be
conducted as ‘black box’ validation). However, even if individual
parts of 'omics studies cannot be addressed in full GLP-compliance,
an ‘as GLP-like as possible’ procedure serves to promote the regu-
latory acceptance of 'omics data.
This introductory lecture was followed by presentations
exploring the feasibility of collecting speciﬁc types of 'omics data
for regulatory purposes in a GLP-compliant manner.
Ben van Ravenzwaay presented a case study to exemplify the
state-of-the-art collection ofmetabolomics data under GLP andGLP-
like conditions. In this case study, all steps of the animal studies
were conducted in-house, under GLP conditions. The metabolome
analysis was undertaken externally in a test facility with GLP status
for mass spectrometry analytics. The different steps of bioanalytical
measurements and archiving of the bioanalytical data were also
conducted following GLP criteria. Only the quality control (QC) and
potential subsequent manual improvements of data (that might be
necessary to improve separation of non-baseline separated peaks in
cases where standard software is unable to handle this) are less than
ideal with respect to GLP requirements. To transparently document
such manual improvements, all individual adjustments must be
recorded in a GLP-like manner. Finally, the interpretation of the
outcomes of the studies was not amenable to GLP criteria since it
required case-by-case expert judgment-based evaluations.
Amber Goetz (Syngenta Crop Protection LLC, USA) reported that
quantitative real-time polymerase chain reaction (qRT-PCR) studies
might or might not be not conducted according to GLP guidelines,
depending on the capabilities of the contract research organisa-
tions. She noted that transcriptomics studies are generally not
conducted according to GLP guidelines. At best, the spirit of GLP can
be maintained by demonstrating that the in vivo studies were
conducted according to GLP and then listing which parts of the
study were not conducted in compliance with GLP. Generally, GLPstandards serve to ensure data integrity, without this being an
assurance of the scientiﬁc merit, or relevance, of the study.
David Rouquie (Bayer CropScience, Sophia Antipolis, France)
presented a GLP perspective of gene expression analyses by qRT-
PCR. These studies are performed both for early phase compound
selection and for product support, i.e. to identify MoAs. All the steps
of the wet lab workﬂow are described in SOPs and can readily be
performed under GLP conditions. By contrast, software validation is
the challenging part that may preclude the achievement of a full
GLP status for the qRT-PCR analysis.
3.2. Summary of breakout session work stream 1
The outcome of the subsequent breakout session Feedback on
the GLP framework served to update the draft yielding the Frame-
work for the quality assurance of 'omics technologies considering GLP
requirements presented in Kauffmann et al. (2017) in this journal
Supplement. The workshop participants agreed that the estab-
lishment of a GLP-like context for collecting, storing and curating
'omics data would be a valuable contribution to fostering the reg-
ulatory acceptance and use of 'omics data. Nevertheless, a key
question raised in the discussions was whether GLP criteria would
alone provide the guidance for conducting high-quality 'omics
studies, or whether more detailed SOPs and analysis criteria, such
as the ones provided by the MAQC consortium, would be required
to capture the levels of detail and ﬂexibility required for accom-
modating the use of 'omics data in regulatory toxicity studies.
Workshop participants deﬁned raw data, in terms of 'omics
technologies, as data produced by the 'omics instruments following
the application of a data acquisition tool (e.g. the data produced
from a microarray scan following the application of the image
analysis software tools provided by the respective vendor). It was
noted that the sheer magnitude of 'omics datasets, and the fact that
such data might exhibit a high degree of between-sample hetero-
geneity and variation as a result of vendors’methods variations, may
pose special challenges for quality assurance auditing. With respect
to the software tools, the availability of audit trails to prevent un-
controlled manipulation was considered especially valuable.
In concluding work stream 1, Ben van Ravenzwaay highlighted
that advancing technology standardisation is essential to improve
best practice for 'omics studies. However, he cautioned that GLP
guidelines serve to ensure the reproducibility of studies, based on
existing raw data, but not necessarily their quality. GLP compliance
ensures the traceability of study results, and it prevents data
manipulation. While audit trails are important (particularly for the
electronic storage of raw data), pending their inclusion in all rele-
vant software, the need for audit trails can be circumvented by
using paper records of the data with every manipulation. If this is
not possible for technical reasons, such as for extremely large
datasets (e.g., RNA-Seq), checksums can be computed on each in-
termediate dataset, storing both the checksums and the datasets.
4. Work stream 2: towards establishing criteria and best
practices for analysing 'omics-based data
Chair: Weida Tong (NCTR, FDA, USA)
4.1. Presentations work stream 2
Timothy W. Gant (Centre for Radiation, Chemical and Envi-
ronmental Effects (CRCEE), Harwell Science and Innovation
Campus, Public Health England (PHE), UK) provided an overview of
the ECETOC framework for the analysis of transcriptomics and other
big data for regulatory application. This framework is presented in
detail in Gant et al. (2017) in this journal Supplement. Since the
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(MIAME; Brazma et al., 2001) and the work of the MAQC con-
sortium (MAQC Consortium et al., 2006; SEQC/MAQC-III
Consortium, 2014) successfully addressed issues to consider in
generating and storing 'omics data, the ECETOC framework focuses
on the second step of 'omics studies, i.e. data processing. Data
processing encompasses (i) the selection of raw data; (ii) data
normalisation; (iii) the ‘ﬁltering’ of data to remove outliers; and (iv)
statistical analysis.
Weida Tong summarised lessons learned from the MAQC and
SEQC projects and presented next steps towards reproducible
'omics for risk assessment. Generally, the reproducibility of DEG
lists can be affected by (i) sample size; (ii) the endpoint under
investigation (reproducibility increases with increasing treatment-
related effect); and (iii) the complexity of the study design (taking
into account the availability of technical and biological replicates).
The MAQC criterion to include fold change and p-value thresholds
to account for cross-laboratory and cross-platform variation as well
as variance ﬁlters to account for signal/noise ratio has improved the
reproducibility of transcriptomics data. For statistical analysis, the
t-test is recommended over the Analysis of Variance (ANOVA)
model, since parameters affecting variance are not necessarily
known and hence cannot be fully accounted for by ANOVA. Further
investigations should aim at assessing how different levels of gene
expression (large versus small modulations) affect reproducibility
and how different approaches to process and analyse tran-
scriptomic data affect the resulting lists of DEGs. Further, it is un-
known how the interpretation of the biological relevance of the
resulting lists of DEGs is affected by the speciﬁc pathway database
used for data interpretation.
Tim Ebbels (Imperial College London, UK) presented a metab-
olomics case study to explore aspects of data processing relevant
for this type of 'omics study. Metabolomics can be applied either in
targeted or untargetedmode, i.e. with or without a prior hypothesis
on the involvement of speciﬁc metabolites. Accordingly, the
experimental design, and particularly the assay technique, de-
termines the range of metabolites that can be observed. In liquid
chromatographyemass spectrometry (LC-MS), which is frequently
used for metabolomics studies, hundreds to thousands of observed
peaks could correspond to hundreds of metabolites (one metabo-
lite can have more than one peak). Since the metabolites are not
identiﬁed, statistical analysis (e.g., between control and test sam-
ples) is typically performed at the peak level. In evaluating data,
peaks will typically have to be aligned to account for differences in
the chromatographic retention times in order to match different
peaks from different samples. Nuclear magnetic resonance (NMR)
techniques are also used for metabolite proﬁling and offer a
reproducible analytical approach with low data variability. How-
ever, the number of analytes is limited due to a lower sensitivity
compared to LC-MS. In NMR, the assignment of peaks to metabo-
lites is encumbered by peak overlap and peak shifts caused by
variations in pH and ionic strength. NMR, LC-MS, and also gas
chromatography - mass spectrometry are frequently used in par-
allel to achieve as broad a coverage of the metabolome as possible.
4.2. Summary of breakout session work stream 2
The outcome of the breakout session Feedback on the framework
of best practices for analysing 'omics data served to update the cor-
responding draft yielding a generic Transcriptomics Reporting
Framework (TRF) for 'Omics Data Processing and Analysis (Gant et al.,
2017) presented in this journal Supplement. Generally, workshop
participants found it premature, or even unfeasible, to provide
speciﬁc guidance on how to conduct the different steps of data
processing. Instead, the imminent value of presenting a frameworkfor reporting the speciﬁc steps of 'omics data processing used in a
particular study was highlighted and proposed as a generic TRF.
Initially focusing on data processing, the TRF should eventually
include parameters for experimental design, and, in the long term,
it might be expanded to cover all types of 'omics (e.g., tran-
scriptomics, proteomics, etc.) and the related technologies (e.g.,
microarrays, RNA-Seq, etc.). The TRF should be organised ﬂexibly to
allow for the inclusion of new evidence, and new methods or new
technologies, as they become available. Adherence to the TRF
would provide transparency on the data processing and evidence
that best practice had been followed, reﬂecting the current matu-
rity of the technology and further taking into consideration the
complexity and diversity of 'omics technologies. Compliance with
the steps of the TRF would enable the generation of reproducible
'omics data, which would facilitate their regulatory applicability.
Also, a Topical Scientiﬁc Workshop on New Approach Methodologies
(that include 'omics-based studies) organised by the European
Chemicals Agency (ECHA, 2016) came to the conclusion that
reporting templates were required for such methodologies to
encourage their use for regulatory purposes.
As such, issues on the reproducibility of 'omics data could relate
to between-study reproducibility as well as to the reproducibility of
the analysis of a given set of raw data. In the future, the TRF could
also provide the basis for the development of technology-speciﬁc
analysis frameworks, in which process the vendors of the tech-
nologies should be involved. Case studies, using reference samples,
and possibly also validation studies, should substantiate the
appropriateness of the steps of the TRF.
In wrapping up work stream 2, Weida Tong and Tim Gant
expressed the wish that the TRF would also be beneﬁcial for the
work of the OECD AOP programme to ensure that all newly
developed AOPs utilising 'omics data are founded on transparently
collected, reproducible data sets. The TRF would be ﬂexible and
sufﬁciently general to accommodate future advancements and new
technologies, while also being sufﬁciently speciﬁc to be useful.
5. Work stream 3: best practices for identifying biological
pathways and developing AOPs to connect 'omics data to the
phenotype
Chair: Alan Poole (ECETOC, Belgium)
Work stream 3 covered the ﬁrst of two topics addressing the
interpretation of 'omics data, i.e. best practices for establishing
biological pathways to connect 'omics data to the phenotype.
5.1. Presentations work stream 3
Beatriz Silva Lima (Faculty of Pharmacy, Lisbon University,
Portugal) presented lessons learned from the Health and Environ-
mental Sciences Institute (HESI) framework for the improved inte-
grated and harmonised regulatory application of non-animal
alternative methods in safety assessments. Established in 2014 as a
multi-stakeholder forum encompassing more than 60 scientists,
the HESI framework aims to deﬁne integration criteria to be used in
assessing the ﬁtness-for-purpose of test methods and testing ap-
proaches for regulatory decision-making. The HESI framework
encompasses three modules, i.e. (i) assay performance; (ii) pre-
diction model performance; and (iii) utilisation of the prediction
model. The HESI framework is especially helpful in assessing IATA
and ITS data. IATAs and ITSs are gaining increasing importance in
regulatory toxicology since animal tests generally cannot be
replaced one-by-one by single non-animal methods. Test methods
addressing speciﬁc key events of an AOP, rather than entire toxi-
cological endpoints, have to be assessed against the speciﬁc bio-
logical alterations rather than against apical effects. To achieve
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the traditional animal tests and the new testing approaches are
applied in parallel and then compared, may prove beneﬁcial.
Further, it was discussed that the GHS/CLP provisions on the C&L of
substances might make it difﬁcult to apply criteria based on
mechanistic information (that formed the basis for IATAs and ITSs)
in regulatory toxicology, rather than apical endpoint data.
Kamin Johnson (Dow Chemical Company, USA) presented a
preliminary proposal to pivot from employing 'omics data for
hazard identiﬁcation to using them to generate bioactivity-based
PoDs for the risk assessment of substances. This tiered approach
is intended to facilitate the application of 'omics data, not only to
investigate MoAs, but also to derive PoDs for regulatory hazard and
risk assessment. Since prevailing knowledge gaps generally make it
difﬁcult to link 'omics data to a speciﬁc apical effect, the goal to
identify an apical effect might be replaced by the goal to determine
bioactivity, i.e. the perturbation of a biological pathway at the
molecular level. If no bioactivity is observed, there should be no
hazard. In a future paradigm, in which bioactivity in combination
with exposure constitutes risk, PoDs could be based upon the
benchmark dose that affects the most sensitive biological path-
way(s) (Thomas et al., 2013a; Farmahin et al., 2017). A tiered
approach for a bioactivity-based risk assessment is envisioned in
which substances with potentially greater health risk (exempliﬁed
by human health assessment) are tested against increasingly
complex biological systems:
 Tier 0: Determination of in vitro bioactivity PoD, e.g., using
in vitro assays from the ToxCast™ program (Judson et al., 2014)
or an 'omics-based analysis of one or more appropriate in vitro
models. Using predictions of human exposure and internal
dosimetry, the in vitro PoD is used to calculate a margin-of-
exposure (MoE; Benford et al., 2010), and substances with a
Tier 0MoE belowa speciﬁc threshold value are submitted toTier
1.
 Tier 1: Determination of in vivo PoD, using 'omics data recorded
for all relevant organs in a short-term repeated-dose toxicity
study. This in vivo PoD is combined with predictions of human
exposure and internal dosimetry to generate a MoE, and sub-
stances with a Tier 1 MoE below a speciﬁc threshold are sub-
mitted to Tier 2
 Tier 2: Generation of bioactivity PoD, using 'omics data recorded
for all relevant organs in an in vivo repeated-dose toxicity study
encompassing all possible critical routes of exposure (e.g. an
extended one generation-like study).
When applying such a bioactivity-based risk assessment
approach, it will have to be considered whether the recorded
bioactivity could ultimately lead to an apical effect. However, the
limited data generated to date comparing 'omics and apical PoDs
for cancer endpoints suggest that these PoDs lie within an order of
magnitude (Bercu et al., 2010; Thomas et al., 2013a, b; Jackson et al.,
2014). Also in a comparative assessment of 104 cases, metab-
olomics proﬁling showed a similar sensitivity as the classical 28-
day rat oral toxicity study conducted in accordance with OECD
Test Guideline 407 (van Ravenzwaay et al., 2014). With respect to
the interpretation of in vitro data, the different sensitivities of
different cell lines might need to be considered. Workshop partic-
ipants suggested that the biggest hurdle to using a bioactivity-
based approach for risk assessment might be the hazard-based
GHS/CLP provisions for the C&L of substances used to communi-
cate toxicological effects.
Richard Meehan (MRC Human Genetics Unit, Western General
Hospital, University of Edinburgh, Scotland) presented preliminary
results from studies using liver tissues from rats and mice (handledin the same way as control groups in 28-day oral toxicity studies
complying with OECD Test Guideline 407) to establish rodent liver
epigenome ground states, i.e. ‘normality’ (European Chemical In-
dustry Council (CEFIC) Long-range Research Initiative (LRI) project
C3). Epigenetics reﬂect changes in gene activity in the absence of
altered DNA sequences, and these are indicative of speciﬁc cell
states. During toxicity testing, the vast majority of epigenetic al-
terations are reversible once the test substance is no longer applied.
Hence, those epigenetic alterations that prevail might be toxico-
logically relevant and have the potential to enhance integrated
pathway analysis in elucidating a substance's MoA.
5.2. Summary of breakout session work stream 3
The subsequent breakout session Connecting results of 'omics
data to phenotype did not serve to update a previously drafted
framework document. Therefore, the following paragraphs (struc-
tured in accordance with the questions posed to the breakout
groups) summarise important results from this session and the
subsequent plenary discussion. This summary focuses on tran-
scriptomics studies, where data interpretation begins with the se-
lection of DEGs.
5.2.1. How can gene expression analysis move away from using
arbitrary fold change thresholds to measures that take appropriate
account of the dynamic expression ranges of different genes?
Frequently, DEGs are selected by assessing fold changes using
thresholds that were set arbitrarily, i.e. without speciﬁc scientiﬁc
justiﬁcation. Taking into account the toxicological context under
investigation, this approach has proven useful, since fold change
thresholds, just as p-values, constitute easily applicable ﬁlters to
condense complex data sets. However, from a biological point of
view, applying fold change thresholds may prevent relevant bio-
logical effects from being observed. In this regard, the biological
evaluation of small gene expression changes may be challenging.
The application of multiple testing adjustment factors may
enable more a stringent statistical ﬁltering of DEGs, than the use of
fold change thresholds. Further alternative approaches to avoid
using arbitrary fold change thresholds may be pathway- or pattern-
matching approaches, applying read-across from common data-
bases to match the generated data. Such approaches consider the
rank orders and the direction of gene expression changes (ECETOC,
2008), but not their amplitude or magnitude. Pathway- or pattern-
matching approaches include a probability analysis of the similarity
of the gene expression proﬁles, which can either be based on
comparative techniques (using, e.g., a pre-deﬁned predictive gene
set or a rank-based correlation analysis) or on multivariate analyses
(e.g., principal component analyses or clustering techniques)
(ECETOC, 2008). Further approaches to avoid fold change thresh-
olds involve the use of generalised linear models, e.g. the bench-
mark dose modelling of the dose-dependence of effects (Thomas
et al., 2013a; Farmahin et al., 2017). An orthogonal approach
avoiding fold change thresholds uses the correlation structure
among genes to reconstruct networks, to identify modules within
these networks, to relate modules to variables of interest (e.g.,
treatment or dose), and to select candidate genes in interesting
modules by their network properties (e.g., association with the
module or hub-gene-like properties; i.e. genes with high whole-
network connectivity (Langfelder et al., 2013)).
5.2.2. How can irrelevant changes in gene expression be
distinguished from meaningful ones?
Generally, gene expression changes should be evaluated for
their biological relevance, statistical signiﬁcance, and technical
reliability and reproducibility. The qualitative and quantitative
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result in phenotypic alterations depends on the biological function
of the respective gene and its overall effect on the biological
pathway or network that it is part of as well as the type of cell under
investigation and themagnitude of effects. In in vivo studies, the life
stage of the animals and the time point of sampling may also affect
the levels of gene expression changes (ECETOC, 2010). An under-
standing of physiological processes and pathways allows placing
gene expression changes into their biological context. Using
pathway databases, recurrent changes that are not of toxicological
interest can be identiﬁed and sorted out (ECETOC, 2013). As it is
unlikely that measurements from a single 'omics technology will
identify all biologically relevant changes, it might be necessary to
have a “fusion” of 'omics derived data to truly distinguish between
meaningful and irrelevant changes linked to a toxicological
outcome. An understanding of the inter-relationship of these
'omics measurements linked to apical pathology will help identify
those measurements reﬂective of a toxicological effect. Such an
approach will require pathway experts collaborating in multi-
disciplinary teams to interpret and agree the relationships be-
tween 'omics measurements and their relationship with toxico-
logically relevant 'omics changes.
Further, the interrelation of genes, just as baseline (or back-
ground) levels of gene expression that are unrelated to the expo-
sure to the given substance under investigation, should be taken
into consideration in determining the toxicological relevance of
gene expression changes (ECETOC, 2010). These parameters may be
accounted for by including appropriate controls in the study and by
using gene expression pattern-based analyses and benchmark dose
modelling of dose-response relationships.
5.2.3. Are changes in the expression of a single gene meaningful? or
should all gene expression changes be considered as a part of a
biological pathway?
The altered expression of a single gene may or may not be
biologically relevant. If a speciﬁc gene encodes a rate-limiting fac-
tor, its altered expression can have major implications for the
phenotype. In this case, this particular gene can constitute a
biomarker of an entire biological pathway. Consideration of the
AOP concept to identify genes and gene products that represent the
MIE or key events of the AOP, or that are considered relevant
proxies for one or more events along the AOP continuum, may
facilitate an evidence-based approach to identify relevant gene(s)
(cf. also Section below on the mapping of 'omics changes to AOPs).
However, individual genesmay operate in more than one biological
pathway, and, generally, substance administration is likely to affect
multiple biological pathways. In interpreting the toxicological im-
plications of changes in the expression of individual genes, further
mechanistic understanding of cell plasticity, i.e. dynamic changes in
gene expression, is required.
Regardless of the possible biological relevance of single gene
expression changes, it was agreed that a combined evaluation of
gene expression changes across different levels of biological orga-
nisation using pathway- or pattern-matching approaches was
much more relevant for regulatory toxicology. It was considered
very unlikely that a regulatory decision would be made on the
altered expression of a single gene alone.
5.2.4. Can 'omics changes be mapped to AOPs and, if so, how will
this information be used?
Generally, the effects of gene expression changes on the
phenotype evolve from alterations in single cell types, to changes in
organs and tissues, and, ultimately, in the entire organism. Cell
type-speciﬁc evaluations of gene expression changes may be of
interest to identify speciﬁc biomarkers or the MIE, or other keyevents, for speciﬁc AOPs. Such evaluations should take into account
if effects are exposure-speciﬁc or time point-speciﬁc.
As knowledge increases, gene expression changes can increas-
ingly be mapped to AOPs (ECETOC, 2013). Examples are the key
events for oxidative stress or cholestasis (cf. list of OECD-approved
AOPs, available at https://AOPwiki.org/oecd_page; accessed 09May
2017). Mechanistic information provided by 'omics technologies
can also be useful to amend already established AOPs or to identify
connections between different AOPs.
AOPs may assist in identifying the relevance of those biological
pathways that are affected for one or more adverse outcomes. For
this purpose, multiple AOP information (AOP networks), captured
in knowledge bases, such as the AOP-wiki (www.AOPwiki.org),
should be utilised. While most currently available AOPs describe
linear sequences of events, AOP networks can be developed to
represent interlinked AOPs (Angrish et al., 2016), and such net-
works may also contain feedback loops. To enable a more effective
use of the associated 'omics data, interrelationships between AOPs
must bemore fully developed, and a comprehensive understanding
of AOPs and the MoAs of substances is required. In this regard,
different biological pathways may represent different levels of
molecular, cellular, or biological organisation, and some biological
pathways are closer to apical effects than others. Therefore, the
integration of different 'omics measurements (e.g. to determine the
transcriptome, metabolome, and proteome) may be necessary to
capture all aspects of an AOP.
Knowledge on AOPs can support read-across and substantiate
the human health relevance of observed apical effects (as well as
the relevance of speciﬁc ITSs). For AOPs to be applicable to hazard
and risk assessment, quantitative measurements are required. For
instance, MIEs or any other key events (further taking into
consideration species- and dose level-speciﬁcity) can be useful to
establish a threshold for an apical effect. Recent advances such as
introduction of quantitative AOPs (Conolly et al., 2017) and
comprehensive WoE evaluation of the individual steps of the AOP
using modiﬁed or tailored Bradford-Hill criteria (Meek et al., 2014;
Becker et al., 2015) will likely facilitate larger implementation of
AOPs within regulatory approaches.
Workshop participants agreed that it was a promising approach
to link gene expression changes and pathway perturbations to the
phenotype by mapping them to speciﬁc AOPs. However, other ap-
proaches were also discussed, such as the mapping of gene
expression changes with signatures of toxicity.
5.2.5. Can genes or biological pathways be identiﬁed where there is
generally a good linkage to phenotypic changes and ones where the
linkage is not very good?
Using phenotypic anchoring approaches, changes in annotated
genes and curated pathways that carry out speciﬁc biological
functions can be linked to functional alterations at the phenotypic
level. While changes in RNA levels are often not accompanied by
cellular or phenotypic alterations, a number of genes and biological
pathways can already be linked to phenotypic changes. Examples
include transcriptional changes that are mechanistically linked to
phthalate ester-induced testicular dysgenesis in rats (Liu et al.,
2005) and changes in the uterus during the oestrus cycle, the cy-
tochrome P450 gene expression (e.g. leading to an increase in
metabolic activity), or exposure to heavy metals and subsequent
metallothionein induction (Fabbri et al., 2012). Again, expert
knowledge is required to establish such links, in addition to dis-
tinguishing between adaptive and adverse effects. At best, such
considerations should address by how many orders of magnitude
adaptive and adverse effects differ, and they should take into ac-
count the dose- and time-dependence of the transition from
normal variability, through adaptive response, to adverse effect
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pathways to be able to assess the orders of magnitude difference
between adaptive and adverse effects. However, it is not always
possible to establish quantitative relationships between gene
expression changes and phenotypic changes. Generally, it was
considered difﬁcult to determine the human health relevance of
'omics data (just as other toxicological data) obtained under very
controlled study conditions at present.
5.2.6. Can expression changes be used as a basis for establishing
safe levels of exposure? If so, how should the dose-response
relationship be assessed? How can expression changes be used to
obtain a PoD?
The workshop participants agreed that further work is neces-
sary before gene expression changes can be used as a basis for
establishing safe levels of exposure and that the present workshop
provided important incentives towards achieving this goal.
Research work must be conducted on a case-by-case basis to
identify potentially relevant biological pathways (or genes) that are
prognostic of speciﬁc apical effects. Biological pathway-speciﬁc
benchmark dose modelling, considering in vivo data, shows
promise for the assessment of dose-response relationships to
determine PoDs. However, such approaches remain to be validated,
and criteria have to be identiﬁed to conduct such validation studies.
To use 'omics to derive a PoD, it should be evident that the iden-
tiﬁed biological pathway is causally related to an adverse effect
(ECETOC, 2008, 2010).
Importantly, the applicability of 'omics-based PoDs depends on
the intended use within regulatory toxicology (e.g. to prioritise
substances for hazard assessment or to exclude the need for further
testing). In most cases, 'omics data are not being used on their own,
but embedded in a tiered process. Thus, frameworks are needed to
enable the integration of 'omics data into lines of evidence, e.g. by
applying the quantitativeWoE approach presented inwork stream4.
Inwrapping up work stream 3, Alan Poole emphasised the need
to discriminate whether 'omics-based studies were intended to be
used to supplement toxicity studies or to supplant toxicity studies.
In the short-term, it might be more likely that 'omics data would be
used to improve a mechanistic understanding of AOPs and to ﬁll
data gaps in incomplete lines of evidence when applying read-
across.
6. Work stream 4: best practices for WoE approaches for
integrating 'omics-based data
Chair: Alan Poole (ECETOC, Belgium)
Work stream 4 covered the second of two topics addressing the
interpretation of 'omics data, i.e. the ECETOC framework for applying
'omics data using quantitative WoE (QWoE) approaches that is pre-
sented in detail in Bridges et al. (2017) in this journal Supplement.
6.1. Presentations work stream 4
Mark Pemberton (Systox Ltd., UK; ECETOC Scientiﬁc Commit-
tee) and Jim Bridges (Surrey University, UK), in two video pre-
sentations, provided further details on the utilisation and
integration of 'omics data within QWoE approaches.
A QWoE approach is deﬁned as the identiﬁcation, objective
analysis and scoring (using predeﬁned scientiﬁcally justiﬁed
criteria) of all potentially relevant studies, for both their reliability
and relevance in testing a hypothesis. Accordingly, the steps of a
QWoE approach comprise the formulation of the hypothesis and
data collection; the assessment of the reliability and relevance of
the studies; the identiﬁcation of critical endpoints; the evaluation
of the concordance of ﬁndings both within and between lines ofevidence; comparisons with ﬁndings for related substances; and,
ﬁnally, the conclusion and the characterisation of uncertainties. The
draft QWoE framework is applicable to any hypothesis, e.g. both to
identify MoAs and to determine PoDs for subsequent hazard
assessment. By providing transparency in the way that data are
evaluated and integrated, it minimises the opportunity for bias and
provides a basis for dialogue between stakeholders. When applying
the QWoE framework to 'omics data, their relative weighting as
compared to traditional toxicological data or within a set of 'omics
data has to be taken into consideration.
Amber Goetz (Syngenta Crop Protection LLC, USA) presented a
case study to demonstrate how 'omics data could support WoE
approaches when assessing the human health relevance of exper-
imental ﬁndings. The hypothesis tested in this study was that the
hepatocarcinogenic MoA of the fungicide Sedaxane is initiated by
activation of the constitutive activated receptor (CAR; Oshida et al.,
2015). The study design encompassed oral 22-day toxicity studies
using male CD-1 mice and in vitro studies using primary hepato-
cytes from rats and humans. Organ weight changes, liver enzyme
activation, CAR3 transactivation and pregnane X receptor (PXR)
activation were assessed. Gene expression changes were evaluated
using qRT-PCR and Agilent microarray technologies. The micro-
array data were analysed using the GeneSpring™ 13 software and
applying >1.5 fold-change and <0.05 p-value thresholds. Bioinfor-
matics analyses were conducted using Ingenuity Pathways Analysis
(IPA™) applying a 2-way ANOVA. Multiple testing correction was
performed using Benjamini-Hochberg false discovery rate. The
analysis showed that the expression of xenobiotic metabolising
enzyme genes and other genes associated with CAR and/or PXR
activation increased in a dose-dependent manner. Changes were
consistent with increased liver cell proliferation observed at higher
doses of Sedaxane. Based upon the genomic alterations, lipid
metabolism pathways, but not inﬂammatory pathways, appeared
to be affected. The ﬁndings from the study conﬁrmed the hypoth-
esis that Sedaxane can induce liver tumours in mice by CAR
activation.
The case study provides a pragmatic example of the application
of 'omics tools in regulatory evaluations. The subsequent discussion
highlighted some of the challenges involved in the conduct and
interpretation of gene expression studies including the selection of
appropriate time points for sample collection, the high degree of
sample-to-sample variability, the evaluation of heterogeneous
cellular populations within tissues, and the distinction between
adaptive and adverse effects.
With respect to the high degree of within-group variability (i.e.
‘noise’) of 'omics studies, it was noted that such ‘noise’ was
observed for samples from test groups and control groups alike. The
‘noise’ was speculated to be partly caused by sample-to-sample
variability from a heterogeneous cell population representative of
the measured tissue sample. The evaluation of single cell types or
even single cells might serve to reduce variability, thereby making
it possible to observe signiﬁcant changes in gene expression also at
very low substance concentrations. While investigations on single
cells might be difﬁcult to conduct, in situ hybridisation or RNA-Seq
are practicable tools for such investigations.
6.2. Summary of breakout session work stream 4
The outcome of the subsequent breakout session Feedback on
best practices for WoE approaches for integrating 'omics data served
to update the draft yielding the Framework for the QWoE of 'omics
data for regulatory purposes (Bridges et al., 2017) presented in this
journal Supplement. The workshop participants agreed that a
QWoE framework would serve to improve the transparency and
reproducibility of decisions derived from WoE approaches.
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tory science when assessing the quality of different types of data
and integrating them for hazard and risk assessment (Roth and
Ciffroy, 2016). Similar approaches have been proposed both for
the MoA and AOP frameworks using modiﬁed or tailored Bradford-
Hill considerations (Meek et al., 2014; Becker et al., 2015).
Importantly, the QWoE framework should not become a ‘new
check box approach’, just as the application of any scoring system
should not override case-by-case expert judgment during hazard
and risk assessment. For this reason, it was also suggested that it
might be more appropriate to name the framework ‘semi-quanti-
tative’ WoE approach. Case studies would serve to assess how
consideration of traditional and 'omics-based data (either in com-
bination or each on their own) within the QWoE affected the
outcome of hazard and risk assessment. Such case studies would
have to distinguish between the use of 'omics data to determine
MoAs and to determine PoDs.
In wrapping up work stream 4, Alan Poole emphasised that the
QWoE framework was intended to ensure transparency of the
process, but not to place undue weight on any given numerical
score. While irrelevant studies could always be ﬁltered out, an
unsubstantiated focus on any single study outcome would be pre-
vented by applying the QWoE framework.
7. Close of the workshop
Closing the workshop, Alan Poole thanked all participants for
their valuable contributions to achieve best practice for the acqui-
sition, storage, processing, and interpretation of 'omics data. After
the workshop, the draft frameworks were amended, taking into
account the recommendations from the breakout sessions and
plenary discussions. The frameworks for a GLP-like context for
collecting, storing and curating data; for the processing of 'omics
data; and for QWoE for integrating 'omics data were conceived as
reporting templates to enhance the standardisation, transparency
and reproducibility of 'omics studies. Overall, this work is closely
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goal of regulatory acceptance and use of 'omics studies.
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